profit from every $100 of sales.
$0$100
AVITA Medical
$15.63-3.52% today
+317.9% in 1 year
1-year low $3.271-year high $17.65
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What AVITA Medical sold, what it kept, and what it did with the cash.
Sales went from $34.4 million in 2022 to $71.6 million in 2025, with -$48.6 million of profit last year.
SalesProfit
AVITA Medical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AVITA Medical | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads AVITA Medical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 34 | 50 | 64 | 72 | |
| 28 | 42 | 55 | 59 | |
| -28 | -43 | -57 | -43 | |
| -26 | -34 | -55 | -41 | |
| -27 | -35 | -62 | -49 | |
| -1.07 | -1.40 | -2.39 | -1.74 | |
| 82.4% | 84.5% | 85.8% | 82.1% | |
| -79.9% | -85.1% | -88.1% | -59.4% | |
| -77.5% | -70.6% | -96.3% | -67.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 98 | 112 | 80 | 56 |
| Cash | 18 | 22 | 14 | 10 |
| Total debt | 1 | 42 | 46 | 46 |
| Total liabilities | 14 | 63 | 75 | 73 |
| 85 | 49 | 4 | -17 | |
| 25 | 25 | 26 | 28 | |
| -24.5% | -29.5% | -88.3% | -117.1% | |
| -31.5% | -72.1% | -1,374.6% | 291.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -38 | -49 | -31 | |
| 1 | 1 | 9 | 2 | |
| -20 | -39 | -58 | -33 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 8 | 13 | 10 |
Valuation
- –
- –
- –
- -7.9×
- 6.9×
- –
- –
- -6.7%
- -9.9%
- 0.0%
Profitability
- 82.1%
- -59.4%
- -67.8%
- -57.6%
- 676.8%
- 23.8%
- 476.6%
- -86.2%
- 676.8%
- 29.1%
Growth
- +27.7%
- –
- +46.5%
- –
- +3.4%
Financial health
- –
- -0.13
- 3.8%
- -8.5×
- 0.57
- 0.46
- 1.27
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 884
Top 19%of 886
Bottom 14%of 987
What analysts expect
- Average price target
- $6.75
- Range
- $3.50 – $10.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.35 | -0.35 | +0.0% |
| Feb 12, 2026 | -0.38 | -0.36 | −4.3% |
| Nov 6, 2025 | -0.46 | -0.43 | −7.0% |
| Aug 7, 2025 | -0.38 | -0.26 | −46.2% |
| May 8, 2025 | -0.53 | -0.39 | −35.9% |
| Feb 13, 2025 | -0.44 | -0.30 | −46.7% |
| Nov 7, 2024 | -0.62 | -0.42 | −47.6% |
| Aug 8, 2024 | -0.60 | -0.59 | −1.7% |
News
AVITA rises as wound care product succeeds in U.S. burn center trialSeeking Alpha · Aug 18, 2026The newest story we have is from Aug 18, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
7No pass
Philip Fisher
60Pass
Peter Lynch
66Pass
Joel Greenblatt
6No pass
Charlie Munger
53No pass
Terry Smith
52No pass
Questions about AVITA Medical
Is AVITA Medical a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AVITA Medical AI analysis
What does AVITA Medical do?
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It is in Medical - Devices.
Does AVITA Medical pay a dividend?
No. AVITA Medical does not pay a dividend at the moment.
Is AVITA Medical stock halal?
Yes. AVITA Medical passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has AVITA Medical stock done over the past year?
Up 317.9% over the past twelve months, to $15.63. It traded between $3.27 and $17.65 and is 11.4% below its high.
Who are AVITA Medical's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with AVITA Medical's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.